The changing epidemiology of meningococcal disease in North America 1945-2010

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 1, 2013, Pages 162-171

  Baccarini, Carmen ^a   Ternouth, Andrew ^b   Wieffer, Heather ^b   Vyse, Andrew ^c  

^a GLAXOSMITHKLINE   (United States)

^b Heron Evidence Development Ltd   (United Kingdom)

^c GSK   (Belgium)

Author keywords

Epidemiology; Literature review; Meningococcal disease; Neisseria meningitides; North America

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CANADA; CAUSAL ATTRIBUTION; CHILD; CONTROLLED STUDY; EPIDEMIC; FATALITY; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; MORTALITY; NEISSERIA MENINGITIDIS; NORTH AMERICA; PRESCHOOL CHILD; REVIEW; SCHOOL CHILD; SEROTYPE; TREND STUDY; UNITED STATES; VACCINATION; VIRUS TYPING;

EPIDEMIOLOGY; LITERATURE REVIEW; MENINGOCOCCAL DISEASE; NEISSERIA MENINGITIDIS; NORTH AMERICA;

CANADA; HUMANS; INCIDENCE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; SEROTYPING; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84874708395     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22302     Document Type: Review

References (69)

1. van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351:1849-59; PMID:15509818; http://dx.doi.org/10.1056/ NEJMoa040845.
2. Centers for Disease Control and Prevention. Manual for the surveillance of vaccine-preventable diseases; 4th edition. Centers for Disease Control and Prevention. 2012.
3. World Health Organisation. Meningococcal meningitis Fact sheet N°141.
4. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853-61; PMID:21075057; http://dx.doi.org/10.1016/S1473-3099(10)70251-6.
5. Soriano-Gabarró M, Wolter J, Hogea C, Vyse A. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region. Expert Rev Anti Infect Ther 2011; 9:761-74; PMID:21905785; http://dx.doi.org/10. 1586/eri.11.89.
6. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006; 19:142-64; PMID:16418528; http://dx.doi.org/10.1128/ CMR.19.1.142-164.2006.
7. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010; 107:19490-5; PMID:20962280; http://dx.doi.org/10.1073/pnas.1013758107.
8. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27(Suppl 2):B51-63; PMID:19477562; http://dx.doi.org/10. 1016/j.vaccine.2009.04.063.
9. Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines 2010; 9:285-98; PMID:20218857; http://dx.doi.org/10.1586/erv.10.3.
10. Racloz VN, Luiz SJ. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect Dis 2010; 10:175; PMID:20565757; http://dx.doi.org/10.1186/1471-2334-10-175.
11. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184-91; PMID:20001736; http://dx.doi.org/10.1086/649209.
12. Hershey JH, Hitchcock W. Epidemiology and meningococcal serogroup distribution in the United States. Clin Pediatr (Phila) 2010; 49:519-24; PMID:20507868; http://dx.doi.org/10.1177/0009922809347797.
13. PHAC. Notifiable diseases online. Accessed Apr. 2010.
14. CDC. ABC surveillance reports. Accessed Oct. 2011.
15. Bennet JV, Young LS. Trends in meningococcal disease. J Infect Dis 1969; 120:634-5; PMID:5346539.
16. Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999; 180:1894-901; PMID:10558946; http://dx.doi.org/10.1086/315158.
17. Schlech WF 3rd, Ward JI, Band JD, Hightower A, Fraser DW, Broome CV. Bacterial meningitis in the United States, 1978 through 1981. JAMA 1985; 253:1749-54; PMID:3871869; http://dx.doi.org/10.1001/jama.1985.03350360075022.
18. Varughese PV. Meningococcal disease in Canada: surveillance summary to 1987. CMAJ 1989; 141:567-9; PMID:2505917.
19. Whalen CM, Hockin JC, Ryan A, Ashton F. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis. JAMA 1995; 273:390-4; PMID:7823384; http://dx.doi.org/10.1001/jama.1995.03520290042027.
20. Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 2010; 50(Suppl 2):S37-44; PMID:20144015; http://dx.doi.org/10.1086/648963.
21. PHAC. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2002, through 31 December, 2003. Can Commun Dis Rep 2006; 32:97-107; PMID:16685767.
22. Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R; Canadian Immunization Monitoring Program, Active (IMPACT). The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J 2009; 28:220-4; PMID:19209096; http://dx.doi.org/10.1097/ INF.0b013e31819040e7.
23. De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J 2011; 30:566-9; PMID:21326136; http://dx.doi.org/10.1097/INF.0b013e31820e8638.
24. World Health Organisation. Weekly Epidemiological Record Year 20. Accessed May 2011.
25. Wiggins GL, Hollis DG, Weaver R. Prevalence of serogroups and sulfonamide resistance of meningococci from the civilian population in the United States, 1964-1970. Am J Public Health 1973; 63:59-65; PMID:4630078; http://dx.doi.org/ 10.2105/AJPH.63.1.59.
26. Meningococcal Disease Surveillance Group. Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis. J Infect Dis 1976; 134:201-4; PMID:823273; http://dx.doi.org/10.1093/infdis/134.2.201.
27. Band JD, Chamberland ME, Platt T, Weaver RE, Thornsberry C, Fraser DW. Trends in meningococcal disease in the United States, 1975-1980. J Infect Dis 1983; 148:754-8; PMID:6313816; http://dx.doi.org/10.1093/infdis/148.4.754.
28. Varughese PV, Carter AO. Meningococcal disease in Canada and serogroup distribution. Can Dis Wkly Rep 1983; 9:177-80.
29. Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989-1991. MMWR CDC Surveill Summ 1993; 42:21-30; PMID:8510639.
30. Tsang RSW, Squires SG, Zollinger WD, Ashton FE. Distribution of serogroups of Neisseria meningitidis and antigenic characterization of serogroup Y meningococci in Canada, January 1, 1999 to June 30, 2001. Can J Infect Dis 2002; 13:391-6; PMID:18159416.
31. Fischer M, Perkins B. Neisseria meningitidis serogroup B: Emergence of the ET-5 complex. Semin Pediatr Infect Dis 1997; 8:50-6; http://dx.doi.org/10. 1016/S1045-1870(97)80009-X.
32. Atkinson W, Wolfe S, Hamborsky J. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. 12 ed. Washington DC: Public Health Foundation. 2011.
33. Tsang RSW, Henderson AM, Cameron ML, Tyler SD, Tyson S, Law DKS, et al. Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada. J Clin Microbiol 2007; 45:1753-8; PMID:17442798; http://dx.doi.org/10.1128/JCM.02134-06.
34. Whitney AM, Coulson GB, von Gottberg A, Block C, Keller N, Mayer LW, et al. Genotypic comparison of invasive Neisseria meningitidis serogroup Y isolates from the United States, South Africa, and Israel, isolated from 1999 through 2002. J Clin Microbiol 2009; 47:2787-93; PMID:19571028; http://dx.doi.org/10. 1128/JCM.00091-09.
35. Advisory Committee Statement. An Advisory Committee Statement (ACS). Statement on recommended use of meningococcal vaccines. http://www.phac-aspc.gc. ca/publicat/ccdr-rmtc/04vol30/dr3003aeng. php. Can Commun Dis Rep 2001; 27: 2-36.
36. Macneil JR, Cohn AC, Zell ER, Schmink S, Miller E, Clark T, et al.; Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J 2011; 30:451-5; PMID:21206392.
37. Doyle TJ, Mejia-Echeverry A, Fiorella P, Leguen F, Livengood J, Kay R, et al. Cluster of serogroup W135 meningococci, southeastern Florida, 2008-2009. Emerg Infect Dis 2010; 16:113-5; PMID:20031054; http://dx.doi.org/10.3201/ eid1601.091026.
38. Advisory Committee Statement. An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS). http://www.phac-aspc. gc.ca/publicat/ccdr-rmtc/ 04vol30/dr3003a-eng.php. Can Commun Dis Rep 2009; 35: 1-40.
39. Havens PL, Garland JS, Brook MM, Dewitz BA, Stremski ES, Troshynski TJ. Trends in mortality in children hospitalized with meningococcal infections, 1957 to 1987. Pediatr Infect Dis J 1989; 8:8-11; PMID:2922245; http://dx.doi.org/10. 1097/00006454-198901000-00003.
40. Feldman RA, Koehler RE, Fraser DW. Race-specific differences in bacterial meningitis deaths in the United States, 1962-1968. Am J Public Health 1976; 66:392-6; PMID:1267089; http://dx.doi.org/10.2105/AJPH.66.4.392.
41. O'Brien JA, Caro JJ, Getsios D. Managing meningococcal disease in the United States: Hospital case characteristics and costs by age. Value Health 2006; 9:236-43; PMID:16903993; http://dx.doi.org/10.1111/j.1524-4733.2006.00113. x.
42. Shepard CW, Rosenstein NE, Fischer M; Active Bacterial Core Surveillance Team. Neonatal meningococcal disease in the United States, 1990 to 1999. Pediatr Infect Dis J 2003; 22:418-22; PMID:12792381; http://dx.doi.org/10.1097/01.inf. 0000066876.77453.04.
43. Squires SG, Pelletier L, Mungai M, Tsang R, Collins F, Stoltz J. Invasive meningococcal disease in Canada, 1 January 1997 to 31 December 1998. Can Commun Dis Rep 2000; 26:177-82; PMID:11107657.
44. Brooks R, Woods CW, Benjamin DK Jr., Rosenstein NE. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis 2006; 43:49-54; PMID:16758417; http://dx.doi.org/10. 1086/504804.
45. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA 1995; 273:383-9; PMID:7823383; http://dx.doi.org/10.1001/jama.1995.03520290035026.
46. Filice GA, Englender SJ, Jacobson JA, Jourden JL, Burns DA, Gregory D, et al. Group A meningococcal disease in skid rows: epidemiology and implications for control. Am J Public Health 1984; 74:253-4; PMID:6198932; http://dx.doi.org/10.2105/AJPH.74.3.253.
47. National Advisory Committee on Immunisation (NACI). An Advisory Committee Statement (ACS). Statement on recommended use of meningococcal vaccines. Can Commun Dis Rep 2001; 27:2-36; PMID:11706686.
48. Squires SG, Deeks SL, Tsang RS. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 1999, through 31 December, 2001. Can Commun Dis Rep 2004; 30:17-28; PMID:14971276.
49. Tyrrell GJ, Chui L, Johnson M, Chang N, Rennie RP, Talbot JA; Edmonton Meningococcal Study Group. Outbreak of Neisseria meningitidis, Edmonton, Alberta, Canada. Emerg Infect Dis 2002; 8:519-21; PMID:11996690; http://dx.doi.org/10.3201/eid0805.010337.
50. Diermayer M, Hedberg K, Hoesly F, Fischer M, Perkins B, Reeves M, et al. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA 1999; 281:1493-7; PMID:10227318; http://dx.doi.org/10. 1001/jama.281.16.1493.
51. Law DKS, Lorange M, Ringuette L, Dion R, Giguère M, Henderson AM, et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol 2006; 44:2743-9; PMID:16891487; http://dx.doi.org/10.1128/JCM.00601-06.
52. Advisory Committee on Immunization Practices. Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46(RR-5):13-21; PMID:9048847.
53. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices. Revised recommendations of the Advisory Committee on Immunization Practices to Vaccinate all Persons Aged 11-18 Years with Meningococcal Conjugate Vaccine. MMWR Morb Mortal Wkly Rep 2007; 56:794-5; PMID:17694617.
54. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of meningococcal conjugate vaccines -Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011; 60:72-6; PMID:21270745.
55. PHAC. Guidelines for the prevention and control of meningococcal disease. Can Commun Dis Rep 2005; •••:31.
56. American Academy of Pediatrics Committee on Infectious Diseases. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics 2005; 116:496-505; PMID:15995007; http://dx.doi.org/10.1542/peds.2005-1314.
57. De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001; 285:177-81; PMID:11176810; http://dx.doi.org/10.1001/jama.285.2.177.
58. De Wals P, Deceuninck G, Boulianne N, De Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 2004; 292:2491-4; PMID:15562128; http://dx.doi.org/10.1001/jama.292.20. 2491.
59. Maiden MC, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737-43; PMID:18271745; http://dx.doi.org/10.1086/527401.
60. CDC. MCV4 1 or more doses. Accessed Apr. 2010.
61. Centers for Disease Control and Prevention (CDC). Vaccination coverage among adolescents aged 13-17 years -United States, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:1100-3; PMID:18846032.
62. Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13 through 17 years-United States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:1117-23; PMID:21866084.
63. National Advisory Committee on Immunization (NACI). Meningococcal C conjugate vaccination recommendations for infants. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2007; 33(ACS-11):1-12; PMID:18064747.
64. PHAC. Advice for consideration of quadrivalent (A, C, Y, W135) meningococcal conjugate vaccine, for use by provinces and territories. Can Commun Dis Rep 2010; •••:36.
65. Siu T, Tang W, Dawar M, Patrick DM. Impact of routine immunization using meningococcal C conjugate vaccine on invasive meningococcal disease in British Columbia. Can J Public Health 2008; 99:380-2; PMID:19009920.
66. Lingappa JR, Al-Rabeah AM, Hajjeh R, Mustafa T, Fatani A, Al-Bassam T, et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis 2003; 9:665-71; PMID:12781005; http://dx.doi.org/10.3201/eid0906.020565.
67. Mueller JE, Borrow R, Gessner BD. Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines. Expert Rev Vaccines 2006; 5:319-36; PMID:16827617; http://dx.doi.org/10.1586/14760584.5.3. 319.
68. Efron AM, Sorhouet C, Salcedo C, Abad R, Regueira M, Vázquez JA. W135 invasive meningococcal strains spreading in South America: significant increase in incidence rate in Argentina. J Clin Microbiol 2009; 47:1979-80; PMID:19357205; http://dx.doi.org/10.1128/JCM.02390-08.
69. Cohn A. Optimizing the adolescent meningococcal vaccination program. Accessed Feb. 2011.